proportional hazards regression. Due to limited number of veno-occlusive disease (VOD) episodes (4), we did not include VOD in the analysis. We examined for potential confounding variable of age, donor, conditioning regimen (Bu cyclophosphamide or Bu fludarabine), disease risk index (DRI) grouped as low/intermediate or high/very high, graft source, thymoglobulin use, GVHD prophylaxis used. Of these, only age and DRI were significant and included in the Cox regression model. Kaplan-Meier (K-M) curves were examined for outcome of RFS and overall survival (OS). Pts with a steady area under the curve (AUC) were considered those in whom AUC achieved was within 15% of goal AUC. In order to address the study question, we divided pts into those in whom calculated AUC was within 15% of target AUC (23 pts) and pts in whom AUC was higher/lower by ≥15% based on the first dose pharmacokinetics (21 pts). We also compared outcomes of pts who needed a change of Bu dose <15% (14 pts) to pts who required a dose change of ≥15% (30 pts). Descriptive statistics for background characteristics, disease and SCT variables are summarized in Figure 1 . Acute and chronic GVHD also did not show any significant difference as an outcome of interest, as shown in Figure 2 . Survival analysis did not show a significant difference in RFS between groups of AUC [HR = 1.6 (.52-4.7), P = .42] or Bu dose [HR = 3.6 (.88-14.4), P = .08], despite adjustment for age and DRI. K-M curves for OS for AUC groups are shown in Figure 3 . Nonparametric tests for differences in time to neutrophil (P = .1 for AUC groups, P = .9 for Bu dose groups) and platelet engraftment (P = .7 for AUC groups, P = .6 for Bu dose groups) showed no significant differences between groups. Conclusion: Therapeutic Bu dosing using first dose pharmacokinetics is an acceptable way to dose Bu, despite the transient variations in AUC levels. The fluctuations that occur due to initial dose determination do not appear to affect outcomes. Additional research with a larger sample size is needed to more confidently describe these relationships.
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Hematopoietic stem cell transplant (HSCT) is an established curative treatment option for hematological malignancies and non-malignant diseases. However, its success is limited by regimen related toxicity (RRT) caused by conditioning regimen drugs. RRT involves damage to the endothelium leading to complications including sinusoidal obstruction syndrome. Among different conditioning drugs, busulfan (Bu) and treosulfan (Treo) (a structural analog of Bu) although used widely in HSCT, exhibit differences in their toxicity profile, the reason still being unclear. Here we compared the effect of these two drugs on endothelial cells to identify the factors causing the differences in toxicity. To evaluate the cytotoxic effect of Bu and Treo, we incubated HHSEC and SK-HEP1 cells with Bu (200, 300 & 500 μM) or Treo (3, 10 & 30 μM) for 48 hours at previously reported concentrations in vitro (Danylesko et al., 2012) . Bu induced a profound morphological change from cobble-stone to a fibroblast like spindle shaped elongated cells by 12 h eventually floating due to dose dependent damage while this morphological change was not observed with Treo. However, both Bu and Treo induced a dose dependent increase in soluble ICAM-1 levels with a concomitant decrease in the total cellular ICAM-1 levels suggesting endothelial activation. Further, Bu treatment induced a dose dependent increase in apoptosis (55% in HHSEC & 39% in SK-HEP1 cells) while Treo, even at 30 μM induced minimal apoptosis (22% in HHSEC & 24% in SK-HEP1 cells) demonstrating that despite activating endothelial cells, Treo caused little/no damage to them. However, Treo induced an increase in acidic vesicular organelles (AVO) and LC3 levels suggesting that the minimal apoptosis to Treo could be due to autophagy. The gene expression profiling by using "Endothelial cell biology RT 2 PCR array" showed maximal upregulation of inflammatory (up to 21 fold), apoptosis related genes (upto 17 fold) with Bu treatment compared to Treo (10 & 8 fold respectively). In addition, Bu upregulated cell adhesion genes like CX3CL1, SELPG & VEGFA while Treo upregulated only SELL. Differential upregulation of unique apoptosis and angiogenesis related genes Occludin (OCLN) (Bu versus Treo: 15 versus 2 fold) and KLK3 (Bu versus Treo: 6 versus 3 fold) were also observed. Immunoblotting confirmed that only Bu induced an increase in OCLN (component of extrinsic apoptotic pathway) but not Treo explaining the differences in the extent of apoptosis induced by Bu/Treo. Taken together, our results suggest that differences in toxicity profile between Bu & Treo could be explained by differential gene expression pattern in endothelial cells. Bu induced endothelial damage leading to apoptosis while Treo has driven the cells towards autophagy. Further studies are ongoing in our lab to elucidate the exact mechanism involved in endothelial damage in order to reverse this damage.
Background: Outcomes for haploidentical transplantation appear to be excellent, however, this novel approach brings toxicities that are particular to its biological and clinical milieu. We previously described occurrence of severe cytokine release syndrome (CRS) after haplo-HCT. Severe CRS was associated with poor clinical outcomes, including transplant related mortality, overall survival, and neutrophil engraftment (Abboud et al., BBMT, 10/2016). Methods: We performed a retrospective review of patients who underwent haplo-HCT transplantation at our institution from 7/2009 through 1/2017. Patients were stratified into three categories by grade of CRS experienced: none (grade 0), mild (grade 1-2) and severe (grade 3-4). Outcomes were assessed. A total of 169 patients were identified, median age at transplant of 52 (19-73), and 40% (67) had active disease at the time of transplant. The most common diagnosis was AML (104 pts). Patients with CRS as determined by the attending physician could be treated with the IL-6 receptor inhibitor tocilizumab at a dose of 6-8 mg/kg. Results: We found a high incidence, 89%, of CRS in our haplo-HCT patients. Among a total of 169 patients, 27 (16%) experienced severe CRS, 108 (64%) had mild CRS, and 17 (10%) patients had no evidence of CRS. The most common manifestations of severe CRS included: fever (100%), respiratory failure (75%), hypotension (83.3%), hepatic failure (25%), renal failure (33.3%). Several patients (4%) suffered neurotoxicity or cardiomyopathy. The patients who suffered from severe CRS had significantly worse overall survival (P < .0001) and transplant related mortality (P < .015). Median overall survival was not met for patients with no or mild CRS. Median overall survival for patients with severe CRS was 7.5 months. By contrast, 89% of patients with no or mild CRS survived beyond 7.5 months. Transplant related mortality was significantly higher in the severe CRS group at 100 days (20.8% versus 7.8%) and one year (30.7% versus 11.9%). A total of 14 (8%) patients were treated with tocilizumab. Ten of them had severe CRS-four had grade 3 and six had grade 4. Mean and median progression free survival in patients with severe CRS who received tocilizumab was 283 days and 96 days, compared with 283 days and 155 days in those who did not receive tocilizumab. The patients who suffered from both minor and severe CRS and were treated with tocilizumab trended towards a lower transplant related mortality. Conclusion: CRS is common after T-cell replete haplo-HCT and severe CRS is associated with poor overall survival and higher transplant related mortality. Therapy directed against IL-6 may decrease treatment related mortality. Future prospective studies are warranted in studying the role of CRS prophylaxis and treatment to prevent transplanted related mortality while preserving relapse free survival in peripheral blood haplo-HCT patients.
